Atorlip 5: Effective Cholesterol Management with Atorvastatin
Atorlip 5
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.00 (0%) | 🛒 Add to cart |
| 90 | $0.60 | $64.50 $54.00 (16%) | 🛒 Add to cart |
| 120 | $0.55 | $86.00 $66.00 (23%) | 🛒 Add to cart |
| 180 | $0.49 | $129.00 $88.00 (32%) | 🛒 Add to cart |
| 270 | $0.46 | $193.50 $123.00 (36%) | 🛒 Add to cart |
| 360 | $0.44
Best per pill | $258.00 $157.00 (39%) | 🛒 Add to cart |
Similar products
Atorlip 5 is a prescription medication containing atorvastatin calcium, specifically formulated to address elevated cholesterol levels and support cardiovascular health. As a member of the statin class of drugs, it works by inhibiting the HMG-CoA reductase enzyme in the liver, thereby reducing the production of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing high-density lipoprotein (HDL) cholesterol. This medication is indicated for patients diagnosed with hypercholesterolemia, including those with familial hypercholesterolemia, or for individuals requiring secondary prevention of cardiovascular events. Proper use under medical supervision can significantly lower the risk of heart attack, stroke, and other atherosclerotic complications. Adherence to prescribed dosing and regular monitoring are essential for achieving optimal therapeutic outcomes.
Features
- Contains 5 mg atorvastatin calcium per tablet
- Film-coated, oval-shaped, white to off-white tablets
- Manufactured under strict pharmaceutical quality standards
- Available in blister packs of 10, 30, or 90 tablets
- Requires prescription and medical supervision for use
- Shelf-stable under recommended storage conditions
Benefits
- Significantly reduces LDL (“bad”) cholesterol levels
- Lowers triglyceride concentrations in the bloodstream
- Moderately increases HDL (“good”) cholesterol
- Reduces the risk of cardiovascular events including heart attack and stroke
- Slows the progression of atherosclerosis
- May reduce the need for invasive cardiac procedures
Common use
Atorlip 5 is primarily prescribed for the management of dyslipidemia in adult patients. It is commonly used to treat primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and mixed dyslipidemia. The medication is also indicated for cardiovascular risk reduction in patients with multiple risk factors but without established coronary heart disease, as well as for secondary prevention in patients with existing cardiovascular disease. Clinical use typically involves combination with dietary modifications, including a cholesterol-lowering diet, and other lifestyle interventions such as regular exercise and smoking cessation when appropriate.
Dosage and direction
The recommended starting dose for most patients is one 5 mg tablet taken orally once daily, with or without food. Dosage may be adjusted based on lipid-lowering response and therapeutic goals, with possible titration to 10 mg, 20 mg, or maximum 40 mg daily under physician guidance. Tablets should be swallowed whole with a glass of water and taken at approximately the same time each day to maintain consistent plasma concentrations. Liver function tests and lipid profiles should be monitored periodically, typically before initiation, at 12 weeks after starting therapy or following dose adjustments, and periodically thereafter.
Precautions
Before initiating Atorlip 5 therapy, physicians should obtain a complete medical history with emphasis on liver disease, renal impairment, thyroid dysfunction, and personal or family history of muscle disorders. Patients should be advised to report any unexplained muscle pain, tenderness, weakness, or brownish discoloration of urine promptly. Regular monitoring of liver enzymes is recommended, with discontinuation if persistent elevations occur. Caution is advised in elderly patients, those consuming substantial quantities of alcohol, and patients with predisposing factors for rhabdomyolysis. The medication may increase HbA1c and fasting serum glucose levels, requiring monitoring in diabetic patients.
Contraindications
Atorlip 5 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. It must not be used during pregnancy, in women who may become pregnant, or during breastfeeding due to potential fetal harm and excretion in human milk. Additional contraindications include hypersensitivity to atorvastatin or any component of the formulation, concurrent use with strong CYP3A4 inhibitors such as itraconazole or clarithromycin, and patients with acute porphyria.
Possible side effects
Common adverse reactions (≥2% of patients) include headache, myalgia, arthralgia, diarrhea, nausea, and increased liver enzymes. Less frequently reported effects include constipation, flatulence, dyspepsia, insomnia, and rash. Serious but rare side effects requiring immediate medical attention include rhabdomyolysis with potential renal failure, hepatotoxicity, immune-mediated necrotizing myopathy, and increased HbA1c levels. Approximately 1-3% of patients may experience mild, transient increases in creatine kinase levels without clinical significance.
Drug interaction
Atorlip 5 undergoes metabolism primarily through CYP3A4, resulting in numerous potential drug interactions. Concomitant use with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors) significantly increases atorvastatin exposure and risk of myopathy. Moderate inhibitors (erythromycin, fluconazole, verapamil) may also increase concentrations. Gemfibrozil and other fibrates increase myopathy risk. Cyclosporine, niacin, colchicine, and anticoagulants may require dose adjustments. Patients should inform healthcare providers of all medications, including over-the-counter drugs and herbal supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. Consistency in daily administration is important for maintaining stable lipid-lowering effects, but occasional missed doses are unlikely to significantly impact long-term cholesterol management when overall adherence is maintained.
Overdose
There is no specific antidote for atorvastatin overdose. Reported cases have been limited, with no fatal outcomes. Suspected overdose should prompt immediate medical attention. Treatment is supportive and symptomatic, with monitoring of vital signs and clinical status. Liver function tests and creatine kinase levels should be assessed. Hemodialysis is unlikely to be effective due to high protein binding. General supportive measures include gastric lavage if ingestion was recent and activated charcoal administration if appropriate.
Storage
Store Atorlip 5 tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original blister packaging or container to protect from light and moisture. Store away from heat sources and direct sunlight. Keep out of reach of children and pets. Do not use tablets beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations or through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Atorlip 5 is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient responses may vary, and therapeutic decisions should be based on professional medical judgment considering the patient’s complete medical history and current condition. The prescribing physician should be consulted for specific dosage recommendations and monitoring requirements. Never initiate, adjust, or discontinue medication without professional medical guidance.
Reviews
Clinical studies demonstrate that atorvastatin 5 mg effectively reduces LDL cholesterol by approximately 30-39% from baseline in most patients. Long-term outcome trials show significant reduction in cardiovascular events with well-tolerated therapy. Patient satisfaction surveys indicate good tolerability profile with most side effects being mild and transient. Real-world evidence supports the effectiveness of low-dose atorvastatin in achieving lipid goals while minimizing adverse effects, particularly in elderly patients and those with mild to moderate hypercholesterolemia.